Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a Phase 2 clinical trial to create a framework for evaluating the safety and effectiveness of multiple investigational treatments for chronic weight management in adults with obesity or overweight. This master protocol includes intervention-specific appendices ISAs that allow for independent evaluation of different treatments as they become available. Participants may receive various drugs, including LY3305677, LY3841136, tirzepatide, LY3549492, macupatide, eloralintide, or placebo. These treatments are administered either subcutaneously or orally, with each ISA detailing specific intervention plans. The study uses a randomized, double-blind, parallel design to assess these interventions. Participants will be involved in screening and treatment phases, with safety and efficacy monitored throughout. The primary outcome measures the number of participants allocated to each ISA from baseline to week 6. The study is sponsored by Eli Lilly and Company and plans to complete by February 2028, enrolling adults aged 18 to 75 years with obesity or overweight under controlled conditions.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orforglipron in adults with overweight who are at risk of developing obesity-related complications such as type 2 diabetes, hypertension, and dyslipidemia, or progressing to class 1 obesity. The study is a phase 3, randomized, double-blind, placebo-controlled trial that aims to understand whether this oral medication can reduce these risks over a two-year period. Participants will be randomly assigned to one of three groups receiving orforglipron orally throughout, orforglipron followed by placebo, or placebo followed by orforglipron. The study involves daily oral administration of these medications. The trial includes a long-term treatment period lasting up to 104 weeks about two years, during which participants are monitored for weight changes and the onset of obesity-related health issues. Throughout the study, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood markers like glycated hemoglobin and triglycerides, and quality of life questionnaires. Researchers will also monitor the time to onset of obesity-related complications and pharmacokinetics of orforglipron at specified intervals. Safety and effectiveness will be tracked continuously, with the primary outcome being the time until the development of obesity-related complications or progression to class 1 obesity.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of macupatide and eloralintide, alone or combined, in managing weight among adults who are overweight or obese but do not have type 2 diabetes. The study is conducted under a master protocol and seeks to understand how these treatments affect body weight changes over time. Participants are randomly assigned to one of several groups to receive macupatide, eloralintide, their combination, or a placebo. All treatments are given through subcutaneous injections. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The main treatment period lasts about 36 weeks, with additional assessments extending to around 64 weeks. During the study, participants will be closely monitored through various visits to assess changes in body weight and body mass index. Researchers will measure the percentage change in body weight from the start of the study to week 36 and beyond. Safety and adherence will also be tracked throughout the study, which lasts approximately 64 weeks in total.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ABBV-295, a long-acting amylin analog, for adults with obesity or overweight who also have weight-related health conditions. The study aims to compare different doses of ABBV-295 with a placebo to see how well they reduce body weight by Week 32. This phase 2 trial involves about 360 adult participants across multiple sites in the United States and Puerto Rico. Participants will be randomly assigned to receive one of several doses of ABBV-295 or a placebo. The treatment is given as subcutaneous injections using pre-filled syringes. Dose escalation will occur during the 52-week Double-Blind Period until reaching a maintenance dose. Participants will not know which treatment they receive, and all groups follow a similar dosing schedule. Throughout the study, participants will attend regular visits at clinics or hospitals for medical assessments, blood tests, and questionnaires to monitor weight changes and any side effects. The primary outcomes include the percentage change in body weight from baseline to Week 32 and the number of participants experiencing adverse events up to Week 52. The study lasts for 52 weeks of treatment with ongoing safety monitoring.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.